Evolent and Standard BioTools Signal Shift to Efficiency in 2025 Results
Evolent and Standard BioTools reported strong 2025 revenue growth, with Evolent crossing the $2.6 billion threshold and Standard BioTools achieving its first positive adjusted EBITDA quarter. Both companies are now pivoting toward margin expansion and operational discipline as they enter the 2026 fiscal year.